Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
JMJD6 and NMYC binding examined by ChIP-seq in NMYC overexpressing CHP134 human neuroblastoma cells
PubMed Full text in PMC Similar studies SRA Run Selector
JMJD6 gene gain is a tumorigenic factor and therapeutic target in neuroblastoma
PubMed Full text in PMC Similar studies
H3K27ac, H3K4me and H3K4me3 binding examined by ChIP-seq in the CHP-134 neuroblastoma cell line
Pol2 binding examined by ChIP-seq in inducible JMJD6 knockdown neuroblastoma cells
Differential gene expression analysis of MYCN-amplified neuroblastoma cells after Doxycycline inducible shRNA knockdown of JMJD6 gene expression
PubMed Full text in PMC Similar studies Analyze with GEO2R
Differential gene expression in neuroblastoma cells after treatment with vehicle control, JQ1, panobinostat, or combination of JQ1 and panobinostat
PubMed Similar studies Analyze with GEO2R
CGH analysis of mouse mammary gland tumors from eight genetically-engineered mouse models
Comprehensive genomic profiling identified miRNA signatures associated with mammary tumor differentiation and development
Genetically engineered murine models of human breast cancer
PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet
Mechanistic basis and efficacy of targeting Beta Catenin-TCF7L2-JMJD6-MYC Axis to overcome resistance to BET inhibitors
Mechanistic basis and efficacy of targeting Beta Catenin-TCF7L2-JMJD6-MYC Axis to overcome resistance to BET inhibitors [no drug]
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Mechanistic basis and efficacy of targeting Beta Catenin-TCF7L2-JMJD6-MYC Axis to overcome resistance to BET inhibitors [OTX015]
Mechanistic basis and efficacy of targeting Beta Catenin-TCF7L2-JMJD6-MYC Axis to overcome resistance to BET inhibitors [ChIP-seq]
Targeting Myc signaling pathway by inhibition of histone demethylase JMJD2B
Targeting Myc signaling pathway by inhibition of histone demethylase JMJD2B (ciclopirox)
Targeting Myc signaling pathway by inhibition of histone demethylase JMJD2B (siRNA)
JMJD6 licenses estrogen receptor alpha-dependent enhancer RNA and coding gene activation by modulating CARM1/MED12 co-activator complex in breast cancer
JMJD6 licenses estrogen receptor alpha-dependent enhancer RNA and coding gene activation by modulating CARM1/MED12 co-activator complex in breast cancer [Gro-Seq]
JMJD6 licenses estrogen receptor alpha-dependent enhancer RNA and coding gene activation by modulating CARM1/MED12 co-activator complex in breast cancer [ChIP-Seq]
A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on